20240024473. HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE simplified abstract (Purdue Research Foundation)
HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE
Organization Name
Inventor(s)
Xiaoping Bao of West Lafayette IN (US)
Qing Deng of West Lafayette IN (US)
Yun Chang of West Lafayette IN (US)
Ramizah Mohd Sabri of West Lafayette IN (US)
HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240024473 titled 'HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE
Simplified Explanation
The present disclosure is about a stage-specific process for manufacturing a population of neutrophils, specifically chimeric antigen receptor-expressing (CAR-expressing) neutrophils, from human pluripotent stem cells (hPSCs). This process involves using defined media and related compositions, kits, and methods of use for targeted cancer immunotherapy.
- The patent application describes a method for generating neutrophils and CAR-neutrophils from hPSCs using chemically defined, feeder-free platforms and stage-specific morphogens.
- The invention also includes cell lines and pharmaceutical compositions related to the manufacturing process.
- The patent application further includes a method of treating cancer using the generated CAR-neutrophils.
- A kit for implementing the stage-specific process is also within the scope of this disclosure.
Potential applications of this technology:
- Targeted cancer immunotherapy: The generated CAR-neutrophils can be used to specifically target and attack cancer cells, potentially improving the effectiveness of cancer treatments.
- Cell therapy: The manufacturing process can be used to produce a population of neutrophils for cell therapy applications, such as treating immune disorders or infections.
Problems solved by this technology:
- Limited availability of neutrophils: Neutrophils are a crucial component of the immune system, but their availability for therapeutic purposes is limited. This technology provides a method for generating a population of neutrophils from hPSCs, overcoming the scarcity issue.
- Specific targeting of cancer cells: CAR-neutrophils can be engineered to express chimeric antigen receptors that recognize and bind to specific cancer cell markers. This allows for targeted destruction of cancer cells while minimizing damage to healthy cells.
Benefits of this technology:
- Scalability: The stage-specific process can be scaled up to produce a large number of neutrophils, ensuring a sufficient supply for therapeutic applications.
- Customizability: The CAR-neutrophils can be engineered to express specific chimeric antigen receptors, allowing for customization based on the target cancer cells.
- Feeder-free and chemically defined platforms: The use of feeder-free and chemically defined platforms reduces the risk of contamination and simplifies the manufacturing process.
Original Abstract Submitted
the present disclosure relates to a stage-specific process for manufacturing a population of neutrophils, such as chimeric antigen receptor-expressing (car-expressing) neutrophils (e.g., t cells and natural killer (nk) cells), from human pluripotent stem cells (hpscs) using defined media and related compositions, kits, and methods of use (e.g., targeted cancer immunotherapy). stage-specific processes for generating neutrophils and chimeric antigen receptor (car) neutrophils from human pluripotent stem cells (hpscs) using chemically defined, feeder-free platforms and stage-specific morphogens; cell lines; pharmaceutical compositions; a method of treating cancer; and a kit are within the scopes of this disclosure.
